[Form 4] GENIE ENERGY LTD Insider Trading Activity

Rhea-AI Filing Summary

Verona Pharma plc (VRNA) – Form 4 filing dated 08/05/2025

Non-executive director Mahendra Shah reported routine equity activity tied to previously granted restricted stock units (RSUs). On 08/01/2025, 24,000 Ordinary Shares (equivalent to 3,000 ADSs; eight Ordinary Shares per ADS) were acquired upon RSU vesting/settlement at $0 exercise price (code “M”). To cover statutory tax withholding, Shah executed a mandatory sell-to-cover of 3,608 Ordinary Shares (451 ADSs) at an average $13.1437 per Ordinary Share (code “S”).

Post-transaction holdings total 93,472 Ordinary Shares (11,684 ADSs) held directly, plus 72,000 RSUs that continue to vest 25% on each of 1 Aug 2025, 1 Nov 2025, 1 Feb 2026 and 1 May 2026, subject to continued service. No cash proceeds were realized from the RSU conversion itself; only the small portion sold for taxes generated proceeds.

The filing reflects normal insider tax-related activity rather than directional buying or selling. Ownership percentage and company fundamentals are essentially unchanged; therefore, the market impact is expected to be negligible.

Insights

Senior Equity Analyst

TL;DR: Routine RSU vesting; small tax sale—neutral signal.

The Form 4 shows a standard RSU settlement for director Mahendra Shah. He converted 24k Ordinary Shares at zero cost and disposed of 3.6k shares solely to meet tax obligations, leaving his net position largely intact (-3.8% of new shares). Remaining 93.5k Ordinary Shares plus 72k unvested RSUs indicate continued alignment with shareholders. No new purchases or discretionary sales occurred, so I view the disclosure as not impactful to valuation or sentiment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDIN AVI

(Last) (First) (Middle)

C/O GENIE ENERGY LTD.

520 BROAD STREET

(Street)

NEWARK NJ 07102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Genie Energy Ltd. [ GNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class B Common Stock, par value $.01 per share	08/01/2025		F		6,791(1)	D	$20.1	114,906(2)	D
Class B Common Stock, par value $.01 per share	08/03/2025		F		6,415(1)	D	$20.15	108,491(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer for tax purposes upon the vesting of Restricted Stock.

2. Consists of 52,043 shares of Class B common stock held directly, 21,463 vested restricted shares of Class B common stock and 41,400 unvested restricted shares of Class B common stock. Of the 41,400 unvested restricted shares, (i) 20,000 shall vest as follows: 10,000 shares shall vest on each of August 3, 2025 and February 10, 2026; and (ii) 21,400 shares shall vest as follows: 10,700 shares shall vest on each of August 3, 2026 and August 2, 2027.

3. Consists of 52,043 shares of Class B common stock held directly, 25,048 vested restricted shares of Class B common stock and 31,400 unvested restricted shares of Class B common stock. Of the 31,400 unvested restricted shares, (i) 10,000 shall vest on February 10, 2026; and (ii) 21,400 shares shall vest as follows: 10,700 shares shall vest on each of August 3, 2026 and August 2, 2027.

	Joyce J. Mason, by Power of Attorney	08/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Verona Pharma (VRNA) shares did Mahendra Shah acquire in this filing?

He acquired 24,000 Ordinary Shares (3,000 ADSs) through RSU settlement at $0 exercise price.

Why were 3,608 Verona Pharma shares sold on 08/01/2025?

The sale was a mandatory sell-to-cover transaction to satisfy tax withholding on the RSU vesting.

What is Mahendra Shah’s total direct ownership after the transactions?

He now holds 93,472 Ordinary Shares, equivalent to 11,684 ADSs.

How many restricted stock units remain unvested for the director?

Shah retains 72,000 RSUs that vest 25% each on 1 Aug 2025, 1 Nov 2025, 1 Feb 2026 and 1 May 2026.

Is this insider activity considered bullish or bearish for VRNA stock?

The filing is largely neutral; it reflects administrative tax-related activity, not discretionary buying or selling.